Association of HLA-G polymorphisms with nasopharyngeal carcinoma risk and clinical outcome

Human Immunology

Volumn 72, Issue 2, 2011, Pages 150-158

  Ghandri, Nahla ^a   Gabbouj, Sallouha ^a   Farhat, Karim ^a   Bouaouina, Noureddine ^a,b   Abdelaziz, Hamdi ^c   Nouri, Abdelatif ^c   Chouchane, Lotfi ^a,d   Hassen, Elham ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^d WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

HLA G; Nasopharyngeal carcinoma; Survival; Susceptibility

Indexed keywords

HLA G ANTIGEN;

ADULT; ALLELE; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; CASE-CONTROL STUDIES; CODON; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; LYMPH NODES; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TREATMENT OUTCOME; TUNISIA;

EID: 78651236975     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.10.006     Document Type: Article

References (77)

1. Chang E.T., Adami H.O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkes Prev 2006, 15:1765-1777.
2. Ferlay J., Bray F., Pisani P., Globocan P.D.M. Cancer Incidence, Mortality and Prevalence Worldwide: IARC Cancer Base.No. 5 2001, International Agency for Research on Cancer, 2000, Lyon, France.
3. Khabir A., Sellami A., Sakka M., Ghorbel A.M., Daoud J., Frikha M., et al. Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res 2000, 6:3932-3936.
4. Ayan I., Kaytan E., Ayan N. Childhood nasopharyngeal carcinoma: From biology to treatment. Lancet Oncol 2003, 4:13-21.
5. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002, 12:431-441.
6. Goldsmith D.B., West T.M., Morton R. HLA associations with nasopharyngeal carcinoma in Southern Chinese: A meta-analysis. Clin Otolaryngol Allied Sci 2002, 27:61-67.
7. Hassen E., Nahla G., Bouaouina N., Chouchane L. The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk. Mol Biol Rep 2010, 37:119-126.
8. Li X., Ghandri N., Piancatelli D., Adams S., Chen D., Robbins F.M., et al. Associations between HLA class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians. J Transl Med 2007, 5:22.
9. Tang M., Zeng Y., Poisson A., Marti D., Guan L., Zheng Y., et al. Haplotype-dependent HLA susceptibility to nasopharyngeal carcinoma in a Southern Chinese population. Genes Immun 2010, 11:334-342.
10. Hirankarn N., Kimkong I., Mutirangura A. HLA-E polymorphism in patients with nasopharyngeal carcinoma. Tissue Antigens 2004, 64:588-592.
11. O'Callaghan C.A., Bell J.I. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev 1998, 163:129-138.
12. Sheu J., Shih IeM. HLA-G and immune evasion in cancer cells. J Formos Med Assoc 2010, 109:248-257.
13. Rouas-Freiss N., Gonçalves R.M., Menier C., Dausset J., Carosella E.D. Direct evidence to support the role of HLA-G in protecting the foetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A 1997, 94:11520-11525.
14. Paul P., Rouas-Freiss N., Khalil-Daher I., Moreau P., Riteau B., Le Gal F.A., et al. HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 1998, 95:4510-4515.
15. Chen H.X., Lin A., Shen C.J., Zhen R., Chen B.G., Zhang X., et al. Up-regulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer. Hum Immunol 2010, 71:892-898.
16. Wiendl H., Mitsdoerffer M., Hofmeister V., Wischhusen J., Bornemann A., Meyermann R., et al. A functional role of HLA-G expression in human gliomas: An alternative strategy of immune escape. J Immunol 2002, 168:4772-4780.
17. Diepstra A., Poppema S., Boot M., Visser L., Nolte I.M., Niens M., et al. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens 2008, 71. 219-6.
18. Ibrahim E.C., Guerra N., Lacombe M.J., Angevin E., Chouaib S., Carosella E.D., et al. Tumor specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 2001, 61:6838-6845.
19. Urosevic M., Kurrer M.O., Kamarashev J., Mueller B., Weder W., Burg G., et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001, 159:817-824.
20. Ugurel S., Rebmann V., Ferrone S., Tilgen W., Grosse-Wilde H., Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-a immunotherapy. Cancer 2001, 92:369-376.
21. Sebti Y., Le Friec G., Pangault C., Gros F., Drénou B., Guilloux V., et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 2003, 64:1093-1101.
22. Carosella E.D., Horuzsko A. HLA-G and cancer. Semin Cancer Biol 2007, 17:411-412.
23. Shiroishi M., Tsumoto K., Amano K., Shirakihara Y., Colonna M., Braud V.M., et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A 2003, 100:8856-8861.
24. Mandelboim O., Pazmany L., Davis D.M. Multiple receptors for HLA-G on human natural killer cells. Proc Natl Acad Sci U S A 1997, 94:14666-14670.
25. Rajagopalan S., Long E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999, 189:1093-1100.
26. LeMaoult J., Zafaranloo K., Le Danff C., Carosella E.D. HLA G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005, 19:662-664.
27. Le Rond S., Azéma C., Krawice-Radanne I., Durrbach A., Guettier C., Carosella E.D., et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells. J Immunol 2006, 176:3266-3276.
28. Le Gal F.A., Riteau B., Sedlik C., Khalil-Daher I., Menier C., Dausset J., et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999, 11:1351-1356.
29. Wiendl H., Mitsdoerffer M., Hofmeister V., Wischhusen J., Weiss E.H., Dichgans J., et al. The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: Implications for myoblast transplantation and gene therapy. Brain 2003, 126:176-185.
30. Rajagopalan S., Bryceson Y.T., Kuppusamy S.P., Geraghty D.E., Van der Meer A., Joosten, et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2006, 4:e9.
31. Fournel S., Aguerre-Girr M., Huc X., Lenfant F., Alam A., Toubert A., et al. Cutting edge: Soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000, 164:6100-6104.
32. Llano M., Lee N., Navarro F., García P., Albar J.P., Geraghty D.E., López-Botet M. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: Preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998, 28:2854-2863.
33. Tang K.F., Chan S.H., Loh K.S., Chong S.M., Wang D., Yeoh K.H., et al. Increased production of interferon-gamma by tumour infiltrating T lymphocytes in nasopharyngeal carcinoma: Indicative of an activated status. Cancer Lett 1999, 140:93-98.
34. Tang K.F., Tan S.Y., Chan S.H., Chong S.M., Loh K.S., Tan L.K., et al. A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: Implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum Pathol 2001, 32:42-49.
35. Khanna R., Busson P., Burrows S.R., Raffoux C., Moss D.J., Nicholls J.M., Cooper L. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): Evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res 1998, 58:310-314.
36. Diehl M., Münz C., Keilholz W., Stevanović S., Holmes N., Loke Y.W., et al. Nonclassical HLA-G molecules are classical peptide presenters. Curr Biol 1996, 6:305-314.
37. Ishitani A., Sageshima N., Lee N., Dorofeeva N., Hatake K., Marquardt H., Geraghty D.E. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol 2003, 171:1376-1384.
38. Lenfant F., Pizzato N., Liang S., Davrinche C., Le Bouteiller P., Horuzsko A. Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice. J Gen Virol 2003, 84:307-317.
39. Heinrichs H., Orr H.T. HLA non-A, B,C class I genes: Their structure and expression. Immunol Res 1990, 9:265.
40. Full List of HLA Class I alleles Anthony Nolan Research Institute, Accessed: 15 April 2010. http://hla.alleles.org/data/txt/g_nuc.txt.
41. Castelli E.C., Mendes-Junior C.T., Deghaide N.H., de Albuquerque R.S., Muniz Y.C., Simc̃es R.T., et al. The genetic structure of 3'untranslated region of the HLA-G gene: Polymorphisms and haplotypes. Genes Immun 2010, 11:134-141.
42. Larsen M.H., Hviid T.V. Human leukocyte antigen-G polymorphism in relation to expression, function, and disease. Hum Immunol 2009, 70:1026-1034.
43. Olerup O., Zetterquist H. HLA DR typing by PCR amplification with sequence specific primers (PCR-SSP) in two hours: An alternative to serological DR typing in clinical practice including donor recipient matching in cadaveric transplantation. Tissue Antigens 1992, 39:225-235.
44. Morales P., Corell A., Martínez-Laso J., Martín-Villa J.M., Varela P., Paz-Artal E., et al. Three new HLA-G alleles and their linkage disequilibria with HLA-A. Immunogenetics 1993, 38:323-331.
45. Matte C., Lacaille J., Zijenah L., Ward B., Roger M. HLA-G and HLA-E polymorphisms in an indigenous African population. The ZVITAMBO Study Group. Hum Immunol 2000, 61:1150-1156.
46. Lin A., Yan W.H., Dai M.Z., Chen X.J., Li B.L., Chen B.G., et al. Maternal human leukocyte antigen-G polymorphism is not associated with pre-eclampsia in a Chinese Han population. Tissue Antigens 2006, 68:311-316.
47. Van Der Ven K., Skrablin S., Engels G., Krebs D. HLA G polymorphisms and allele frequencies in Caucasians. Hum Immunol 1998, 59:302-312.
48. Castelli E.C., Mendes-Junior C.T., Viana de Camargo J.L., Donadi E.A. HLA G polymorphism and transitional cell carcinoma of the bladder in a Brazilian population. Tissue Antigens 2008, 72:149-157.
49. Simc̃es R.T., Gonçalves M.A., Castelli E.C., Júnior C.M., Bettini J.S., Discorde M.L., et al. HLA-G polymorphisms in women with squamous intraepithelial lesions harbouring human papillomavirus. Mod Pathol 2009, 22:1075-1082.
50. Ober C., Aldrich C.L. HLA G polymorphisms: Neutral evolution or novel function?. J Reprod Immunol 1997, 36:1-21.
51. Hviid T.V., Hylenius S., Hoegh A.M., Kruse C., Christiansen O.B. HLA G polymorphisms in couples with recurrent spontaneous abortions. Tissue Antigens 2002, 60:122-132.
52. Ober C., Aldrich C.L., Chervoneva I., Billstrand C., Rahimov F., Gray H.L., et al. Variation in the HLA-G promoter region influences miscarriage rates. Am J Hum Genet 2003, 72:1425-1435.
53. Hviid T.V. HLA-G in human reproduction: Aspects of genetics, function and pregnancy complications. Hum Reprod Update 2006, 12:209-232.
54. Hviid T.V., Hylenius S., Rørbye C., Nielsen L.G. HLA G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 2003, 55:63-79.
55. Rebmann V., Van Der Ven K., Pässler M., Pfeiffer K., Krebs D., Grosse-Wilde H. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 2001, 57:15-21.
56. Chen X.Y., Yan W.H., Lin A., Xu H.H., Zhang J.G., Wang X.X. The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. Tissue Antigens 2008, 72:335-341.
57. Suárez M.B., Morales P., Castro M.J., Fernández V., Varela P., Alvarez M., et al. A new HLA-G allele (HLA-G*0105N) and its distribution in the Spanish population. Immunogenetics 1997, 45:464-465.
58. Hviid T.V., Meldgaard M., Sørensen S., Morling N. Polymorphism of exon 3 of the HLA-G gene. J Reprod Immunol 1997, 35:31-42.
59. Ishitani A., Kishida M., Sageshima N., Yashiki S., Sonoda S., Hayami M., et al. Re-examination of HLA-G polymorphism in African Americans. Immunogenetics 1999, 49:808-811.
60. Moreau P., Dausset J., Carosella E.D., Rouas-Freiss N. Viewpoint on the functionality of the human leukocyte antigen-G null allele at the fetal-maternal interface. Biol Reprod 2002, 67:1375-1378.
61. Navarro F., Llano M., Bellón T., Colonna M., Geraghty D.E., López-Botet M. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 1999, 29:277-283.
62. Le Discorde M., Le Danff C., Moreau P., Rouas-Freiss N., Carosella E.D. HLA G *0105N null allele encodes functional HLA-G isoforms. Biol Reprod 2005, 73:280-288.
63. Rouas-Freiss N., Marchal R.E., Kirszenbaum M., Dausset J., Carosella E.D. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: Is HLA-G the public ligand for natural killer cell inhibitory receptors?. Proc Natl Acad Sci U S A 1997, 94:5249-5254.
64. Hviid T.V., Møller C., Sørensen S., Morling N. Co-dominant expression of the HLA-G gene and various forms of alternatively spliced HLA-G mRNA in human first trimester trophoblast. Hum Immunol 1998, 59:87-98.
65. Hassen E., Farhat K., Gabbouj S., Jalbout M., Bouaouina N., Chouchane L. TAP1 gene polymorphisms and nasopharyngeal carcinoma risk in a Tunisian population. Cancer Genet Cytogenet 2007, 175:41-46.
66. Farhat K., Hassen E., Bouzgarrou N., Gabbouj S., Bouaouina N., Chouchane L. Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokines 2008, 43:132-137.
67. Farhat K., Hassen E., Gabbouj S., Bouaouina N., Chouchane L. Interleukin-10 and interferon-gamma gene polymorphisms in patients with nasopharyngeal carcinoma. Int J Immunogenet 2008, 35:197-205.
68. Jalbout M., Bel H., Jrad B., Bouaouina N., Gargouri J., Yacoub S., et al. Autoantibodies to tubulin are specifically associated with the young age onset of the nasopharyngeal carcinoma. Int J Cancer 2002, 101:146-150.
69. Khabir A., Ghorbel A., Daoud J., Frikha M., Drira M.M., Laplanche A., et al. Similar BCL-X but different Bcl-2 levels in the two age groups of north African nasopharyngeal carcinomas. Cancer Detect Prev 2003, 27:250-255.
70. Hviid T.V., Sørensen S., Morling N. Polymorphism in the regulatory region located more than 1.1 kilobases 5' to the start site of transcription, the promoter region, and exon 1 of the HLA-G gene. Hum Immunol 1999, 60:1237-1244.
71. Solier C., Mallet V., Lenfant F., Bertrand A., Huchenq A., Le Bouteiller P. HLA G unique promoter region: Functional implications. Immunogenetics 2001, 53:617-625.
72. Ober C., Billstrand C., Kuldanek S., Tan Z. The miscarriage-associated HLA-G -725G allele influences transcription rates in JEG-3 cells. Hum Reprod 2006, 21:1743-1748.
73. Yie S.M., Li L.H., Xiao R., Librach C.L. A single base-pair mutation in the 3'-untranslated region of HLA-G mRNA is associated with pre-eclampsia. Mol Hum Reprod 2008, 14:649-653.
74. Ooi E.E., Ren E.C., Chan S.H. Association between microsatellites within the human MHC and nasopharyngeal carcinoma. Int J Cancer 1997, 74:229-232.
75. Lu C.C., Chen J.C., Tsai S.T., Jin Y.T., Tsai J.C., Chan S.H., et al. Nasopharyngeal carcinoma-susceptibility locus is localized to a 132 kb segment containing HLA-A using high-resolution microsatellite mapping. Int J Cancer 2005, 115:742-746.
76. Tse K.P., Su W.H., Chang K.P., Tsang N.M., Yu C.J., Tang P., et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am J Hum Genet 2009, 85:194-203.
77. Sala F.G., Del Moral P.M., Pizzato N., Legrand-Abravanel F., Le Bouteiller P., Lenfant F. The HLA-G *0105N null allele induces cell surface expression of HLA-E molecule and promotes CD94/NKG2A-mediated recognition in JAR choriocarcinoma cell line. Immunogenetics 2004, 56:617-624.